Showing results (141-150 of 154) with videos related to

Sort By:
Pageof 16
Annals of the Rheumatic Diseases|December 24, 2008
From gene expression to serum proteins: biomarker discovery in ankylosing spondylitisN Haroon, F W L Tsui, F D O'Shea, et al.
Clinical and Experimental Rheumatology|July 1, 2008
Bacterial triggers and autoimmune rheumatic diseasesH J Girschick, L Guilherme, R D Inman, et al.
Rheumatology (Oxford, England)|June 10, 2008
Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare IllustrationM A Stone, E Pomeroy, A Keat, et al.
Arthritis and Rheumatism|June 1, 1982
Adult-onset Still's disease. Twenty-year followup and further studies of patients with active diseaseK B Elkon, G R Hughes, E G Bywaters, et al.
Blood|August 1, 1983
Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpuraJ B Bussel, R P Kimberly, R D Inman, et al.
Clinical and Experimental Rheumatology|January 7, 2014
Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritisB Hugle, R Burgos-Vargas, R D Inman, et al.
Annals of the Rheumatic Diseases|April 22, 2005
Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeksJ C Davis, D M van der Heijde, J Braun, et al.
Annals of Internal Medicine|December 1, 1993
Occurrence of antibodies to Borrelia burgdorferi in patients with nonspirochetal subacute bacterial endocarditisA T Kaell, P R Redecha, K B Elkon, et al.
Arthritis and Rheumatism|February 16, 2010
Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trialJ D Carter, L R Espinoza, R D Inman, et al.
Annals of the Rheumatic Diseases|October 31, 2007
Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitisJ C Davis, D M van der Heijde, J Braun, et al.
Pageof 16